The Macular Disease Society has joined forces with three other charities to appeal against a NICE decision not to recommend Lucentis on a cost basis that could lead to thousands of people with diabetes losing their sight.
Together with Diabetes UK, Juvenile Diabetes Research Foundation and the Royal National Institute of Blind People, it is calling for Lucentis to be made available on the NHS to treat diabetic macular oedema.
The charities argue that other key stakeholders have not been able to comment on significant new evidence submitted to NICE by the drug's manufacturer and are calling for a proper consultation allowing stakeholders to submit their evaluations.
Register now to continue reading
Thank you for visiting Optician Online. Register now to access up to 10 news and opinion articles a month.
Register
Already have an account? Sign in here